Weve been talking a lot about GLP-1 this year
European Society of Cardiology #HFA Heart Failure Policy Network GICC SFC SFC - Socit Franaise de Cardiologie Kevin Damman Guillaume Baudry Jan Biegus To view or add a comment, sign in AstraZeneca is joining the cardiology community at the European Society of Cardiology congress 2025 to discuss the latest innovations in reducing the global burden of cardiovascular, renal and metabolic (CVRM) diseases which drove around 21 million deaths in 2021 alone
But the drugs arent effective for about 14% of people who try them
Contact us if youd like to request reuse of a visual asset
Botanical Extracts (In General) The Claims : A broad range of plant extracts are marketed for their metabolic benefits, often claiming to influence GLP-1 secretion or mimic its effects through antioxidant or anti-inflammatory pathways
Yes, certain GLP-1 receptor agonists (liraglutide, injectable semaglutide and dulaglutide) have demonstrated cardiovascular benefits in major trials, including reduced risk of heart attack, stroke and cardiovascular death in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors